The withdrawal of rimonabant, a CB1R antagonist, used for the treatment of obesity due to risk of suicide and depression has received increased interest in the role of the CB1R in affecting mood and affective behavior. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.